Parkinson's Disease (PD) is a progressive neurological condition. It affects about 1:1000 people overall but about 1:100 of the elderly and up to 1:10 in nursing home residents. The disease affects around 120,000 people in the UK.

PD is progressive, disabling and distressing.

The National Institute for Clinical Excellence (NICE) released guidelines for the treatment and management of PD in June 2006. These are soon to be reviewed. The Wirral PD Planning Group have developed these guidelines to assist you in managing patients with this complex disease.

**DIAGNOSIS STAGE: PARKINSON'S DISEASE GUIDELINES**

**PD Suspected**

Features of PD are:-
- Slowness
- Stiffness
- Tremor (at rest, usually starts unilaterally)
- Loss of balance/Falls

Check Prescription for Antidopaminergics
- e.g. Prochlorperazine (Stemetil), Metoclopramide, Haloperidol and other anti-psychotics

Refer Untreated to Specialist PD Clinic (NICE Guidelines 2006)
- New referrals should be seen within 6 weeks
  - <60 years
  - >60yrs
- Neurologist/Physician or Neurologist specialising in PD
- Walton Centre / WUTH (Dr M O' Neill / Consultant Neurologist)

**Referral to Therapies:-**
- Physiotherapy – Sharon Chapman / Sue Mansfield
- Speech and Language Therapy – Beth Bell
- Dietetics – Catherine Cliff
- Occupational Therapy
- Aids and Adaptations
- Access to ‘Advice & Education groups’ for newly diagnosed patients via Consultant or PDNS (Nuala Browning / Rachel Gregson)

Diagnosis of PD

Yes

Consider Referral to Parkinson's Disease Nurse Specialist (PDNS) for regular access to additional support and advice:
- Telephone 0151 643 5330
- Fax 0151 643 5440

Refer on to Multi-disciplinary teams for intervention as required

No

Consider Referral to Parkinson’s Disease Nurse Specialist (PDNS) for regular access to additional support and advice:
- Telephone 0151 643 5330
- Fax 0151 643 5440

Refer on to Multi-disciplinary teams for intervention as required

**MAINTENANCE AND COMPLEX STAGE: PARKINSON'S DISEASE GUIDELINES**

**MOTOR COMPLICATIONS**
- Freezing/festination
- End of dose deterioration
- On/Off phenomenon
- Dyskinesias
- Dystonia
- Postural instability

Consider referral for:
- Physio and OT
- Speech/Language therapy
- Dietician
- Social services

Financial Support

Referral to PDNS (new referrals should be seen within 6 weeks or 2 weeks if complex - NICE 2006)

Regular review and monitoring of patients

**PSYCHOLOGICAL COMPLICATIONS**
- Anxiety levels
- Depression
- Apathy
- Panic attacks
- Paranoia
- Psychosis
- Dementia

**NON-MOTOR COMPLICATIONS**
- Pain
- Fatigue
- Dysphagia
- Autonomic Dysfunction i.e. Sexual dysfunction, Bowel & Bladder problems
- Postural Hypotension
- Sleep Disorders

**USEFUL CONTACTS**

PDNS (Parkinson's Disease Nurse Specialist)
- Tel: 643 5330
- Wirral CT, 1st floor Civic Medical Centre, Bebington
- Fax: 643 5301

Parkinson’s Information and Support Worker (Welfare Advice)
- Tel: 03442253658

Parkinson’s Disease UK Helpline
- Tel: 0808 800 0303

Social Services (Central Advice and Duty Team)
- Tel 606 2006

Age UK Wirral
- Tel: 666 2220

Citizens Advice Bureau
- Tel: 0844 477 2121

Wired and Wirral Carers
- Tel: 670 0777

**WEBSITES:**
- NICE Guidelines - [www.nice.org.uk](http://www.nice.org.uk)
- Parkinson’s Disease Society - [www.parkinsons.org.uk](http://www.parkinsons.org.uk)

**REFERENCES**

- National Institute for Health & Clinical Excellence (NICE) Guideline 35: Parkinson’s Disease in Primary and Secondary Care June 2006
- Parkinson’s Aware in Primary Care. A Guide for Primary Care Teams developed by: The Primary Care Taskforce for the PDS (UK) 1000

1\textsuperscript{st} line \textbf{Levodopa e.g. Co-beneldopa, co-careldopa}

- Relief of bradykinesia, rigidity, tremor and improvement of ADLS
- Low acquisition cost
- TDS administration
- Slow titration to therapeutic dose to avoid adverse effects
- Long term: can lead to motor fluctuations and dyskinesias
- Dispersible form available Co-beneldopa – quicker onset of action and easier to swallow.

1\textsuperscript{st} line \textbf{Dopamine agonists e.g. ropinirole, pramipexole}

- Long acting, once daily preparations available if tablet burden problematic
- Lower incidence of long term motor fluctuations and dyskinesias
- Less effective for bradykinesia and improving ADLs
- Adverse effects: hallucinations, low blood pressure, sudden onset of sleep, confusion in older patients and possible gambling / hypersexuality or punding
- Rotigotine patch may be used for patients intolerant of or unable to take other dopamine agonists or those with prominent nocturnal /early morning symptoms. Also indicated in patients that are nil by mouth or unable to swallow where appropriate. See Wirral clinical guideline – ‘Parkinson’s Disease Initial Medical and Surgical Management Checklist (rotigotine conversion table)’

**Inadequate symptom control / unable to tolerate dopamine agonist:**
- Replace with/add in levodopa

Severe dyskinesias consider amantadine:
- Relieves moderate dyskinesias
- Rapid response
- Effects mild and unsustained
- Confusion with higher doses

1\textsuperscript{st} line \textbf{MAOBIs. Selegiline/rasagiline}

- Once daily administration
- Possible disease modifying effect
- Adverse effects: confusion, postural hypotension (especially with selegiline)
- Mild efficacy
- Interactions with SSRIs / pethidine and nasal decongestants (pseudoephedrine)

Rasagiline may be used for patients intolerant of or unable to take other MAOBI’s or where compliance is a concern

1\textsuperscript{st} line \textbf{Anticholinergics. Trihexyphenidyl (benzhexol)}

- Used in young patients where tremor predominates
- Use Benzhexol and titrate slowly
- Adverse effects: dry mouth, urinary retention, constipation, blurred vision, impaired cognitive function
- Rarely indicated in older patients due to risk of confusion, orphenadrine may occasionally be used

**Apopomorphine is used for a number of indications:**

1. For patients with persistent motor fluctuations who are still responsive to dopaminergics, who have failed to respond sufficiently to maximum recommended doses or are intolerant of, or cannot take because of contraindications, other dopaminergic agents e.g. dopamine agonists, MAOBI and COMTI; AND who are prepared to consider an injectable preparation and have the necessary support to make that possible. This will follow an apomorphine trial to establish responsiveness and minimum effective dose (in most cases).

2. For patients who are unable to take oral medications - usually temporarily e.g. for surgery or in ITU etc but who are dopaminergic responsive.

3. For patients with neuroleptic malignant syndrome.

Later disease with motor fluctuations

- Increase frequency of levodopa
- Add dopamine agonist to levodopa, may require dosage adjustment of levodopa
- Add entacapone (COMTI) to levodopa (can use combination product - Sastravi). If intolerant of entacapone then consider tolcapone (consultant only)
- Modest effect in most patients
- Add MAOBI - selegiline/rasagiline
- Propranolol/metoprolol reduce postural and action tremor. Consider anticholinergic if appropriate (see above)
- Apomorphine. Persistent motor fluctuations unresponsive to above measures or where adverse effects from other dopamine treatments are unacceptable.
- Use Duodopa where severely handicapped by motor fluctuations, despite above – Tertiary Centre – WCNN.

Parkinson’s Disease – Clinical Guideline v8

Approved by Medicines Clinical Guidance Team: Sept 2016

Review Date: Sept 2019
## Prescribing Information for Non-Motor Features of Parkinson’s Disease

This guidance provides information on the drug choices that will minimise interactions and adverse effects in patients already receiving treatment for Parkinson’s Disease (PD). Treatment for complex PD-related problems should be initiated in secondary care.

<table>
<thead>
<tr>
<th>Problem</th>
<th>Recommendation</th>
<th>Cautions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depression. The clinical features may overlap with motor features of PD</td>
<td>Best choice: SSRIs, particularly sertraline (NB increased risk of serotonin syndrome with all antidepressants and selegiline &amp; rasagiline)</td>
<td>Avoid: Tricylics – poorly tolerated as they can worsen cognitive problems, constipation and autonomic dysfunction</td>
</tr>
<tr>
<td>Psychosis and hallucinations. Do not treat mild psychotic symptoms if patient and carer can tolerate them</td>
<td>Reduce medication first where possible starting with anticholinergics then TCADs, MAOBl, Amantadine, Dopamine agonists, COMTl, Apomorphine and finally L-Dopa. Best choice: Quetiapine (start at 25mg – usual dose 75mg) If dementia present then start at a lower dose. Where hallucinations present with dementia then consider starting acetylcholinesterase inhibitor rivastigmine (Consultant in Movement Disorders use only. on going prescriptions to be provided from hospital)</td>
<td>Avoid: Haloperidol and all other antipsychotics (quetiapine &amp; clozapine are the safest from the PD point of view). If clozapine is needed, a Psychiatry referral is necessary.</td>
</tr>
<tr>
<td>Anxiety and panic attacks</td>
<td>Best choice: Psychological management. Short term tranquillisers (lorazepam) only if essential.</td>
<td>Avoid antipsychotics. Benzodiazepines may antagonise levodopa</td>
</tr>
<tr>
<td>Moderate dementia and Lewy body dementia</td>
<td>Best choice: Rivastigmine (Specialist initiation only). May improve cognition, hallucinations &amp; delusions but tremor may deteriorate.</td>
<td>Avoid in patients with heart block and epilepsy. Caution with asthma, and COPD and in patients with gastric or duodenal ulcers. Nausea and vomiting can be a problem</td>
</tr>
<tr>
<td>Sleep disturbance</td>
<td>Take a full sleep history – there are many causes of poor sleep in PD. Provide sleep hygiene and relaxation advice. Zopiclone can be used short-term if the problem is not due to a movement disorder / dopamine replacement treatment. In REM Sleep Disorder clonazepam can be used 500mcg to 2mg at night.</td>
<td>Refer back to specialist service if PD medication may need adjusting</td>
</tr>
<tr>
<td>Daytime hypersomnolence</td>
<td>This is common particularly with dopamine agonists – consider reduction of this. Modafinil may be considered – this is an unlicensed indication</td>
<td>Avoid in moderate to severe uncontrolled hypertension and ischaemic heart disease Modafinil can cause severe rashes.</td>
</tr>
<tr>
<td>Nocturnal akinesia</td>
<td>Refer back to specialist service as medication may need adjusting or modified release preparations or dopamine agonists may be appropriate</td>
<td></td>
</tr>
<tr>
<td>Nausea and vomiting. Side effect of PD medication (however tolerance can develop)</td>
<td>Best choice: Domperidone or Cyclizine Rarely, use of ondansetron is justified (not with apomorphine)</td>
<td>Avoid: Metoclopramide, prochlorperazine and other phenothiazines (dopamine antagonists) Caution with high dose domperidone in elderly patients as risk of prolonged QT interval. Needs ECG before initiation.</td>
</tr>
<tr>
<td>Constipation</td>
<td>Best choice: more fibre in diet, increase mobility and fluid intake. Then a mild laxative such as macrogol.</td>
<td>Avoid strong laxatives that may cause faecal incontinence but can use senna, macrogol, suppositories and enemas if needed.</td>
</tr>
<tr>
<td>Problem</td>
<td>Recommendation</td>
<td>Caution</td>
</tr>
<tr>
<td>---------</td>
<td>----------------</td>
<td>---------</td>
</tr>
<tr>
<td><strong>Gastro-oesophageal reflux</strong></td>
<td>Best choice: H2 blockers and PPIs</td>
<td></td>
</tr>
<tr>
<td><strong>Dysphagia</strong></td>
<td>May require investigation: refer to Speech and Language. If severe weight loss, refer to dietetic service. Levodopa helps with dysphagia so co-beneldopa dispersible could be helpful.</td>
<td>Dopamine agonists do not help with dysphagia. NG or PEG feeding may be required.</td>
</tr>
<tr>
<td><strong>Falls (Very common)</strong></td>
<td>Conduct a full falls assessment (NICE CG21). Consider prescribing alendronic acid with calcium and vitamin D to reduce fracture risk where appropriate.</td>
<td>Be particularly aware of detection of postural hypotension and consider treatment for osteoporosis</td>
</tr>
<tr>
<td><strong>Sialorrhoea</strong></td>
<td>Hyoscine patches can be used but only if patient is not confused. The PD UK suggests sucking clove sticks. Atropine 1% eye drops twice daily in the mouth can be used (unlicensed indication).</td>
<td>Hyoscine and atropine can exacerbate urinary retention. Causes confusion, drowsiness and dizziness.</td>
</tr>
<tr>
<td><strong>Urinary dysfunction</strong></td>
<td>Refer patients with refractory or persistent bladder problems to a urologist as a comprehensive assessment is needed. Trospium is less likely to cause anticholinergic effects of confusion.</td>
<td>Anticholinergics should be used with caution as they cross the blood-brain barrier.</td>
</tr>
<tr>
<td><strong>Erectile dysfunction</strong></td>
<td>Phosphodiesterase inhibitors plus lots of support and advice. This is free for patients on NHS scripts.</td>
<td></td>
</tr>
<tr>
<td><strong>Orthostatic hypotension. Side effect of levodopa/dopamine replacement medications and feature of autonomic dysfunction in condition.</strong></td>
<td>Increase fluids and sodium intake. Refer back to specialist service. Prescribe fludrocortisone (salt retaining steroid). Can use support tights. Midodrine is an unlicensed medication option where fludrocortisone is not unsuccessful.</td>
<td>Reduce or eliminate antihypertensive medication.</td>
</tr>
<tr>
<td><strong>Sweating and flushing attacks</strong></td>
<td>May respond to propranolol, starting with 10mg tds and increasing as necessary and if tolerated</td>
<td>Not to be given to patients with contraindications to beta-blockers</td>
</tr>
</tbody>
</table>

**Drugs that interact with Parkinson’s medication**
Iron and pyridoxine interact with Levodopa. Give at different times of day. Benzodiazepines may antagonise the effects of levodopa. A high protein diet may affect levodopa absorption.

**When to refer back to the specialist service**
Poorly controlled disease. Specific PD related problems Adverse effects such as dysphagia, weight loss, severe hallucinations NB: When initiating changes in PD medication, the specialist service will prescribe the first two months supply

**Other points of contact for medication advice**
PD specialist nurses 0151 643 5330 (Monday – Friday 9-5pm)
Medicines Management Team mlcsu.medsmanagementwirral@nhs.net (Monday - Friday 9-5pm)

**Guidelines written by:**
Helen Dingle, Clinical Effectiveness Pharmacist, Wirral PCT
Paula Morgan, Formerly PD Pharmacist, WUTH NHS Trust
Alison Monaghan, Formerly PD Specialist Nurse,
Reviewed by: Dr M O Neill Consultant in Elderly Medicine, WUTH
Nuala Browning, PD Nurse Specialist, Wirral Community NHS Foundation Trust,
Geraldine McKerrell, DME Pharmacist WUTH
Helen Dingle, Medicines Optimisation Pharmacist, MLCSU

**Parkinson’s Disease – Clinical Guideline v8**
Approved by Medicines Clinical Guidance Team: Sept 2016 Review Date: Sept 2019